Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after Praxis CEO Marcio Souza said the chances of the trial being futile were “less than 3%,” the biotech has learnt the study looks unlikely to meet its primary endpoint at an interim analysis.

Nxera Pharma has sold the Asia-Pacific rights to its phase 3 autoimmune drug to Viatris for $10 million upfront.

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a buyout that went for $3 per share. Mirati and Ipsen’s former CEO David Meek, who currently chairs Sobi, will take the reins at bluebird upon the deal’s close, which is expected to be in the first half of this year.

This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease.

The Trump administration is moving urgently to remake health departments in its vision. Federal workers worry the actions will impair the nation’s healthcare system in countless ways,

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed that she took a 16% pay cut in 2024, it also laid out a new compensation plan which could make her one of the highest-paid chief executives in the industry this year.

A rumored private equity buyout of Walgreens could lead the company to be split up, according to media reports.